PALISADE BIO, INC. Payments for Repurchase of Warrants
Shares the company repurchased and the cash it paid, as filed in its 10-Q and 10-K XBRL (statement of shareholders' equity and cash flow statement).
- PALISADE BIO, INC. payments for repurchase of warrants for the quarter ending 2022-09-30 was $0.00.
- PALISADE BIO, INC. payments for repurchase of warrants for the quarter ending 2021-12-31 was $0.00.
- PALISADE BIO, INC. payments for repurchase of warrants for the quarter ending 2021-09-30 was $0.00.
- PALISADE BIO, INC. payments for repurchase of warrants for the quarter ending 2020-12-31 was $0.00.
- PALISADE BIO, INC. payments for repurchase of warrants for fiscal 2021 was $99.00K.
- PALISADE BIO, INC. payments for repurchase of warrants for fiscal 2020 was $0.00.
| Period end | Payments for Repurchase of Warrants 3 month | Payments for Repurchase of Warrants 12 month |
|---|---|---|
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | |
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | $99.00K 10-K · filed 2022-03-17 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | |
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | $0.00 10-K · filed 2022-03-17 |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |